Candel Therapeutics Announces Release of Initial Data on CAN-2409 in a Phase 2 Clinical Trial Showing Cytotoxic T Cell Response and Disease Control in Patients with Non-Small Cell Lung Cancer
26 mai 2022 17h30 HE
|
Candel Therapeutics
Disease control rate of 87.5 percent achieved in patients who were all progressing on anti-PD-1 therapy at trial entryDurable disease stabilization that was ongoing at data cutoff in 62.5 percent of...
Candel Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
18 mai 2022 08h00 HE
|
Candel Therapeutics
NEEDHAM, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today...
Candel Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
12 mai 2022 08h00 HE
|
Candel Therapeutics
NEEDHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a late clinical stage biopharmaceutical company focused on helping patients fight...
Candel Therapeutics to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
27 avr. 2022 16h00 HE
|
Candel Therapeutics
NEEDHAM, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today...
Candel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Highlights
29 mars 2022 08h00 HE
|
Candel Therapeutics
NEEDHAM, Mass., March 29, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a late clinical stage biopharmaceutical company focused on helping patients fight...
Candel Therapeutics Appoints Seshu Tyagarajan, Ph.D., RAC, as Chief Technical and Development Officer
02 mars 2022 08h00 HE
|
Candel Therapeutics
NEEDHAM, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today...
Candel Therapeutics Announces $25 Million Non-dilutive Debt Financing Agreement with Silicon Valley Bank
01 mars 2022 08h00 HE
|
Candel Therapeutics
Additional capital extends cash runway into Q4 of 2023 NEEDHAM, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL) (the “Company” or “Candel”), a late clinical stage...
Candel Therapeutics Appoints Dr. Francesca Barone as Chief Scientific Officer
03 févr. 2022 08h00 HE
|
Candel Therapeutics
NEEDHAM, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today...
Candel Therapeutics to Present at Two Upcoming Investor Conferences
05 janv. 2022 08h00 HE
|
Candel Therapeutics
NEEDHAM, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today...
Bionaut Labs and Candel Therapeutics Announce Strategic Collaboration in Precision-Targeted Delivery of Oncolytic Viral Immunotherapies
15 déc. 2021 05h00 HE
|
Candel Therapeutics
Companies will work on preclinical development of remote-controlled microscale robots to deliver novel oncolytic viral immunotherapies in specific brain tumors LOS ANGELES and NEEDHAM, Mass., Dec. ...